JP2018533937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533937A5 JP2018533937A5 JP2018518466A JP2018518466A JP2018533937A5 JP 2018533937 A5 JP2018533937 A5 JP 2018533937A5 JP 2018518466 A JP2018518466 A JP 2018518466A JP 2018518466 A JP2018518466 A JP 2018518466A JP 2018533937 A5 JP2018533937 A5 JP 2018533937A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- cdr2
- cdr1
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 230000027455 binding Effects 0.000 claims description 30
- 210000002966 serum Anatomy 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 25
- 229910052731 fluorine Inorganic materials 0.000 claims 20
- 229910052717 sulfur Inorganic materials 0.000 claims 16
- 229910052721 tungsten Inorganic materials 0.000 claims 10
- 229910052727 yttrium Inorganic materials 0.000 claims 10
- 229910052740 iodine Inorganic materials 0.000 claims 8
- 229910052698 phosphorus Inorganic materials 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 238000007792 addition Methods 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 229910052700 potassium Inorganic materials 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 101710187898 60S ribosomal protein L28 Proteins 0.000 claims 2
- 102220606724 Syndecan-1_L27E_mutation Human genes 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 102220492414 Ribulose-phosphate 3-epimerase_H35A_mutation Human genes 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000007918 pathogenicity Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 7
- 241000282567 Macaca fascicularis Species 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000000533 capillary isoelectric focusing Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510647977 | 2015-10-09 | ||
| CN201510647977.7 | 2015-10-09 | ||
| PCT/CN2016/101560 WO2017059813A1 (zh) | 2015-10-09 | 2016-10-09 | 抗乙肝表面抗原的抗体及其用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020210762A Division JP2021063092A (ja) | 2015-10-09 | 2020-12-18 | Ｂ型肝炎表面抗原に対する抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533937A JP2018533937A (ja) | 2018-11-22 |
| JP2018533937A5 true JP2018533937A5 (enExample) | 2019-01-10 |
| JP6949012B2 JP6949012B2 (ja) | 2021-10-13 |
Family
ID=58487306
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018518466A Active JP6949012B2 (ja) | 2015-10-09 | 2016-10-09 | Ｂ型肝炎表面抗原に対する抗体及びその使用 |
| JP2020210762A Withdrawn JP2021063092A (ja) | 2015-10-09 | 2020-12-18 | Ｂ型肝炎表面抗原に対する抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020210762A Withdrawn JP2021063092A (ja) | 2015-10-09 | 2020-12-18 | Ｂ型肝炎表面抗原に対する抗体及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10689434B2 (enExample) |
| EP (1) | EP3360896B1 (enExample) |
| JP (2) | JP6949012B2 (enExample) |
| KR (1) | KR102132604B1 (enExample) |
| CN (1) | CN106565840B (enExample) |
| AU (1) | AU2016334290B2 (enExample) |
| BR (1) | BR112018007121A2 (enExample) |
| CA (1) | CA3001231C (enExample) |
| ES (1) | ES3041684T3 (enExample) |
| WO (1) | WO2017059813A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017059813A1 (zh) * | 2015-10-09 | 2017-04-13 | 厦门大学 | 抗乙肝表面抗原的抗体及其用途 |
| JP7490574B2 (ja) * | 2018-05-31 | 2024-05-27 | ノバルティス アーゲー | Ｂ型肝炎抗体 |
| JP6790307B2 (ja) * | 2018-05-31 | 2020-11-25 | 第一三共株式会社 | 抗ヒトｔｌｒ７抗体 |
| WO2020130138A1 (ja) * | 2018-12-21 | 2020-06-25 | 国立大学法人広島大学 | 抗ｐｒｅＳ１抗体およびその用途 |
| US20220251173A1 (en) * | 2019-05-23 | 2022-08-11 | Xiamen University | Anti-hepatitis b virus antibodies and use thereof |
| CN111242107B (zh) * | 2020-04-26 | 2021-03-09 | 北京外号信息技术有限公司 | 用于设置空间中的虚拟对象的方法和电子设备 |
| WO2024148263A1 (en) * | 2023-01-06 | 2024-07-11 | Victorian Infectious Diseases Reference Laboratory | Methods and compositions for antibody treatment of hepatitis b infection |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004517636A (ja) * | 2000-10-02 | 2004-06-17 | コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー | Ｂ型肝炎ウイルスの表面抗原ｓに対するヒト化抗体及びその製造方法 |
| CN1560081A (zh) * | 2004-02-17 | 2005-01-05 | 大连帝恩生物工程有限公司 | 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用 |
| EP2250198B1 (en) | 2008-01-23 | 2016-03-09 | Department of Biotechnology | A humanized high affinity recombinant antibody against hepatitis b surface antigen |
| KR101072895B1 (ko) * | 2009-12-24 | 2011-10-17 | 주식회사 녹십자 | Ｂ형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체 |
| CN102786592A (zh) | 2011-05-17 | 2012-11-21 | 傅阳心 | Hbv特异性抗体 |
| AU2013276015B2 (en) | 2012-06-11 | 2017-04-20 | Xiamen University | Polypeptides and antibodies for treating HBV infection and related diseases |
| HRP20190393T1 (hr) * | 2012-07-10 | 2019-04-19 | Green Cross Corporation | Pripravak protutijela namijenjen sprječavanju ili liječenju infekcije mutantnim virusom hepatitisa b |
| AU2015206002B2 (en) | 2014-01-16 | 2020-06-11 | Mario Umberto Francesco MONDELLI | Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen |
| WO2017059813A1 (zh) * | 2015-10-09 | 2017-04-13 | 厦门大学 | 抗乙肝表面抗原的抗体及其用途 |
-
2016
- 2016-10-09 WO PCT/CN2016/101560 patent/WO2017059813A1/zh not_active Ceased
- 2016-10-09 US US15/766,593 patent/US10689434B2/en active Active
- 2016-10-09 KR KR1020187013043A patent/KR102132604B1/ko active Active
- 2016-10-09 ES ES16853117T patent/ES3041684T3/es active Active
- 2016-10-09 CA CA3001231A patent/CA3001231C/en active Active
- 2016-10-09 AU AU2016334290A patent/AU2016334290B2/en active Active
- 2016-10-09 BR BR112018007121-8A patent/BR112018007121A2/pt active Search and Examination
- 2016-10-09 JP JP2018518466A patent/JP6949012B2/ja active Active
- 2016-10-09 EP EP16853117.6A patent/EP3360896B1/en active Active
- 2016-10-09 CN CN201610879693.5A patent/CN106565840B/zh active Active
-
2020
- 2020-12-18 JP JP2020210762A patent/JP2021063092A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533937A5 (enExample) | ||
| JP2023075294A (ja) | 抗ｃｄ４７抗体及びその応用 | |
| CN102958537B (zh) | TNF-α结合蛋白 | |
| US10836829B2 (en) | Anti-WT1/HLA-specific antibodies | |
| JP2018532383A5 (enExample) | ||
| KR102553752B1 (ko) | 인터페론 알파 및 오메가 항체 길항제 | |
| AR111249A1 (es) | Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares | |
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| WO2012125680A1 (en) | Methods of treating vasculitis using an il-17 binding molecule | |
| JP6949012B2 (ja) | Ｂ型肝炎表面抗原に対する抗体及びその使用 | |
| CN109069606B (zh) | 干扰素β抗体及其用途 | |
| KR102058381B1 (ko) | 인간 ｌ１ｃａｍ에 대한 인간화 항체 및 그의 제조 방법 | |
| US12252539B2 (en) | Anti-FLT3 antibodies and compositions | |
| JP6247646B2 (ja) | ヒト化抗ｈｍｇｂ１抗体もしくはその抗原結合性断片 | |
| CN119487079A (zh) | 一种pvrig/tigit双特异性抗体药物组合物及其用途 | |
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний | |
| JP7752620B2 (ja) | 抗ｉｌ－４ｒ抗体医薬組成物及びその使用 | |
| RU2018129180A (ru) | Тромбиновое антитело, антиген-связывающий фрагмент и их фармацевтическое применение | |
| KR20220079561A (ko) | 항-줄기세포 인자 항체 및 이의 사용 방법 | |
| KR20220116506A (ko) | 다중-특이적 항체 | |
| CN110114372A (zh) | 用于减少多特异性抗体聚集的抗体构架 | |
| RU2844744C1 (ru) | Антитела против фактора стволовых клеток и способы их применения | |
| US20220127349A1 (en) | Antibodies with reduced immunogenicity | |
| WO2025172588A1 (en) | Bispecific constructs directed against fap and ltbr | |
| JP2024074278A (ja) | Ｌａｇ－３およびｐｄ－１／ｌａｇ－３抗体 |